Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies Influencing My Practice Following EACS 2021—Dr. Chloe Orkin

October 27-30, 2021; London, United Kingdom
Hear from CCO’s expert faculty, Dr. Chloe Orkin, as she presents her insights on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations, and more.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Released: November 17, 2021

Information on this Educational Activity

Faculty

Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has reported that she has received consulting fees, fees for non-CME/CE services, and funds for research support from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Dr Yan Zhao discusses data from IDWeek 2022 on long-term benefits of early vs delayed treatment initiation in people with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings